Clinical and laboratory characteristics of patients with febrile neutropenia in a children's hospital in Pasto-Colombia
Main Article Content
Abstract
DOI: 10.1016/j.rcpe.2016.05.001
Introduction
Approximately 40 children under the age of 18 are diagnosed annually with cancer at the Hospital Infantil Los Angeles (HILA) in Pasto, Colombia. Neutropenic fever is a predictable occurrence in these children.
Aim
This study attempts to identify their clinical and laboratory characteristics during 2013.
Methods
Retrospective analysis of all cases of neutropenic fever in paediatric oncology patients seen in the HILA in 2013.
Results
A total of 52 episodes of neutropenic fever were identified in 32 individual patients, of whom two presented with four discrete episodes each. The mean age of the children was 7.2 years and the majority (62%) were male. The most common underlying malignancy was acute lymphoblastic leukaemia. Half of the patients were diagnosed while an in-patient. An absolute neutrophil count of less than 100 cells/mm3 was observed in 5% of cases. The temperatures most commonly ranged between 38 and 38.9 degrees Celsius. The respiratory and gastrointestinal tracts were the most frequently identified sources of infection, and the most commonly used antibiotic treatment regimen was the combination of piperacillin/ tazobactam and amikacin. Sepsis was the most common complication seen, resulting in the death of one child.
Conclusions
Neutropenic fever is a frequent cause of hospital admission in paediatric oncology patients, and this study confirms similar findings in other studies as regards patient age, sex, underlying diagnosis, symptoms upon admission, and mortality. Febrile neutropenia associated with cancer is classified as High Risk. (SLIPE Consensus).
Downloads
Article Details
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer. Consenso de la Sociedad Latinoamericana de Infectología Pediátrica
Rev Chil Infectol, 28 (2011), pp. S10-S38
2 M.E. Santolaya,R. Rabagliati,T. Bidart,E. Payá,A.M. Guzmán,R. Morales
Consenso de manejo racional del paciente con cáncer, neutropenia y fi ebre
Rev Chil Infect, 22 (2005), pp. S79-S111
3 B. Phillips,R. Wade,L.A. Stewart,A.J. Sutton
Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people
Eur J Cancer., 46 (2010 Nov), pp. 2950-2964 http://dx.doi.org/10.1016/j.ejca.2010.05.024
Medline
4 W.T. Hughes,D. Armstrong,G.P. Bodey,E.J. Bow,A.E. Brown,T. Calandra
2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Clin Infect Dis, 34 (2002), pp. 730-751 http://dx.doi.org/10.1086/339215
Medline
5 J. Matera
Neutropenia febril en pediatría. Curso Continuo de actualización en pediatrìa
Precop., 12 (2013), pp. 33-45
6 F. López
Febrile neutropenia in children
Medwave, 8 (2008), pp. e1663
7 K. Ducasse,J.P. Fernandez,C. Salgado,A.M. Alvarez,C.L. Aviles,A. Becker
Characterization of episodes of febrile neutropenia in children with acute myeloid leukemia and acute lymphoblastic leukemia
Rev Chilena Infectol, 31 (2014), pp. 333-338 http://dx.doi.org/10.4067/S0716-10182014000300013
Medline
8 M. Aviles-Robles,R.P. Ojha,M. Gonzalez,K. Ojeda-Diezbarroso,E. Dorantes-Acosta,B.E. Jackson
Bloodstream infections and inpatient length of stay among pediatric cancer patients with febrile neutropenia in Mexico City
Am J Infect Control., 42 (2014), pp. 1235-1237 http://dx.doi.org/10.1016/j.ajic.2014.07.021
Medline
9 A. Cox,N. Bradford
Management of febrile neutropenia in pediatric oncology acrossQueensland, Australia: a retrospective review on variations between locations
J Pediatr Oncol Nurs., 31 (2014), pp. 28-33 http://dx.doi.org/10.1177/1043454213514793
Medline
10 C. Rincón
Caracterización de episodios de neutropenia febril en niños con cáncer en la Fundación Hospital de la Misericordia. (Tesis presentada como requisito para optar al título de Especialista en Pediatría)
Universidad Nacional de Colombia, (2013)
11 Paganini H, Aguirre C, Puppa G, Garbini C, Javier R G, Ensinck G, Febrile Neutropenia Study Group, et al. Prospective, multicentric scoring system to predict bacteremia in febrile neutropenic children with cancer. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago September 17-20, 2007, Abstract N° 2424.
12 Dufort,G. Alvarez
Guía para el tratamiento del paciente con neutropenia febril
Arch Pediatr Urug, 80 (2009), pp. 37-41
13 L. White,M. Ybarra
Neutropenic fever
Emerg Med Clin North Am., 32 (2014), pp. 549-561 http://dx.doi.org/10.1016/j.emc.2014.04.002
Medline
14 M.K. Keng,M.A. Sekeres
Febrile neutropenia in hematologic malignancies
Curr Hematol Malig Rep., 8 (2013), pp. 370-378 http://dx.doi.org/10.1007/s11899-013-0171-4
Medline
15 T. McCavit,N. Winick
Time-to-Antibiotic Administration as a Quality of Care Measure in Children with Febrile Neutropenia: A Survey of Pediatric Oncology Centers
Pediatr Blood Cancer., 58 (2012), pp. 303-305 http://dx.doi.org/10.1002/pbc.23148
Medline
16 H. Paganini,C. Aguirre,G. Puppa,C. Garbini,J. Ruiz Guiñazú,G. Ensinck,C. Vrátnica,L. Flynn,M. Iacono,P. Zubizarreta,Febrile Neutropenia Study Group
A Prospective, Multicentric Scoring System to Predict Mortality in Febrile Neutropenic Children With Cancer
Cancer., 109 (2007), pp. 2572-2579 http://dx.doi.org/10.1002/cncr.22704
Medline
17 T. Lehrnbecher,R. Phillips,S. Alexander,F. Alvaro,F. Carlesse,B. Fisher,H. Hakim,M. Santolaya,E. Castagnola,B.L. Davis,L.L. Dupuis,F. Gibson,A.H. Groll,A. Gaur,A. Gupta,R. Kebudi,S. Petrilli,W.J. Steinbach,M. Villarroel,T. Zaoutis,L. Sung
International Pediatric Fever and Neutropenia Guideline Panel. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation
J Clin Oncol., 30 (2012), pp. 4427-4438 http://dx.doi.org/10.1200/JCO.2012.42.7161
Medline
18 Phillips RS1,A.J. Sutton,R.D. Riley,J.C. Chisholm,S.V. Picton,L.A. Stewart,PICNICC Collaboration
Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol)
Syst Rev., 1 (2012), pp. 8 http://dx.doi.org/10.1186/2046-4053-1-8
Medline
19 M.E. Santolaya,A. Álvarez,C.L. Avilés,A. Becker,J. Cofré,N. Enríquez
Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia
Clin Infect Dis, 35 (2002), pp. 678-683 http://dx.doi.org/10.1086/342064
Medline